drugset / Trial / NCT00704132

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

NCT00704132

Phase 1 Completed 57 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.

Timeline

Start
2007-02-14
Primary completion
2010-04-28
Completion
2010-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 100 mg Oral